Opus Genetics, founded with a mission to revolutionize treatments for ultra-rare blinding conditions, is a science-driven gene therapy company. The company's core vision is to overcome the manufacturing challenges that impede the development of therapies for inherited retinal diseases (IRD). Opus Genetics focuses on creating groundbreaking gene therapies specifically designed for patients with these rare eye conditions, ensuring a patient-first approach in all its endeavors.
Notable affiliations include backing from the Foundation Fighting Blindness’s venture philanthropy fund, which underscores the company's credibility and commitment to its mission. Key achievements include advancing a robust pipeline of gene therapy programs aimed at addressing various IRDs. Opus Genetics' impact is significant in the field of ophthalmology, offering hope and potential cures for patients with previously untreatable genetic eye disorders.
